Vertex Pharma strategy in cystic fibrosis, shares anchored in the NASDAQ-100 healthcare field

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-27, 12:28.

Vertex Pharma (US92532F1003) stands out on the NASDAQ-100 as a profitable specialist in cystic fibrosis therapies, backed by robust cash flows and a growing gene-editing pipeline according to recent comparative coverage of Vertex Pharmaceuticals and CRISPR Therapeutics. A Motley Fool analysis highlights Vertex as an established leader in cystic fibrosis with substantial cash generation.

Where Vertex sits in healthcare

Vertex Pharma’s core business is centered on cystic fibrosis treatments, an area where Vertex Pharmaceuticals is described as dominating the global market with high-margin therapies and significant recurring revenue. The Motley Fool comparison notes that Vertex’s cystic fibrosis portfolio underpins a strong financial position relative to its gene-editing partner CRISPR Therapeutics, while both companies share profits from their joint therapy CASGEVY.

In the broader healthcare equity universe, Vertex’s NASDAQ-100 membership places it in a peer group with other large-cap biotech names, with analysts considering the stock a more established, cash-generative holding compared to earlier-stage gene-editing peers. The same study frames Vertex as a company that balances innovation with a mature revenue base.

Long-term strategy and pipeline focus

Beyond cystic fibrosis, Vertex Pharma’s long-term strategy, as described for Vertex Pharmaceuticals, includes expanding into gene-editing and other serious diseases through partnerships and internal R&D, with CASGEVY highlighted as a key collaborative product with CRISPR Therapeutics. The analyst article points out that Vertex’s pipeline diversification is designed to complement its existing cystic fibrosis franchise.

The comparative view from equity research commentary indicates that Vertex Pharma’s approach emphasizes maintaining profitable core therapies while selectively investing in high-potential innovations, contrasting Vertex’s risk profile with that of CRISPR Therapeutics, which is more dependent on future gene-editing success. The Motley Fool comparison underscores that Vertex’s valuation reflects both its current profitability and expectations for these new programs.

How Vertex Pharma makes money

Vertex Pharma’s revenue base is primarily driven by its cystic fibrosis therapies, which for Vertex Pharmaceuticals are described as a dominant market position with high-margin, recurring sales supported by established products and broad patient coverage. Analyst commentary notes that these treatments form the backbone of Vertex’s cash flow and fund its pipeline investments in gene-editing and other severe disease areas.

Where the stock trades today

Vertex Pharma shares (US92532F1003) trade on NASDAQ as part of the NASDAQ-100 index, with the listing in US dollars and reflecting the company’s status as a large-cap healthcare stock; the latest verifiable closing price for Vertex Pharmaceuticals on NASDAQ was 491.34 US dollars as of 2026-06-26, 16:00 Eastern Time, according to price data providers for the VRTX ticker. The same data source shows an after-hours indication at 489.40 US dollars as of 20:00 Eastern Time on that date.

This article is for informational purposes only and does not contain investment advice, buy or sell recommendations or price targets. All data are based on sources considered reliable at the time of review but may change without notice.